LumiCyte's Strategy to Accelerate Drug Development
Formal launch of protein discovery & validation services using Seldiography
Fremont, CA, August 13, 2001 – LumiCyte, Inc. announced yesterday at a press conference held during the Drug Discovery Technology 2001 meeting in Boston, MA that it has entered the next phase of its development to provide new medical knowledge from its groundbreaking technology to partner pharmaceutical & biotechnology companies.
"This new phase in LumiCyte's development is focused on forming partnerships with pharmaceutical and biotechnology companies with drugs in development. LumiCyte's products enable its partners to accelerate their drug development activities and successfully complete clinical trials," said Anthony D. Bashall, Vice President of Business Development. "We have shown through our collaborations that the new medical knowledge derived from our unique protein biomarker profiles has immediate utility in healthcare delivery. In addition to partnering we will continue to from collaborations with centers of clinical excellence worldwide and actively seek participants in LumiCyte's Cancer Biology Fellowship"
LumiCyte is continuing to aggregate and integrate information exponentially from genomics, proteomics, and clinical sources together with its proprietary protein biomarker profiles in its BioPhore Knowledgebaseä. LumiCyte expects that its BioPhore Knowledgebase will rapidly expand to become the world's largest and most comprehensive source of human biofluid secreted protein knowledge.
On Monday, August 13th LumiCyte will occupy its expansion site next to its current facility. "In order to grow at our projected rate it was clear that LumiCyte needed additional space," said James Immer, Vice President of Operations. "The additional space adjacent and connected to our current site will increase our operational capacity significantly." LumiCyte will host a number of potential partners at its newest facility in the fourth quarter of 2001 where LumiCyte will demonstrate its capabilities and infrastructure.
LumiCyte is in discussions with a number of major pharmaceutical and biotechnology companies to provide its protein mapping and validation services and information products. LumiCyte uses its unique Seldiographyä process. This process consisting of fully integrated proprietary protein mapping BioChips with advanced SELDI readers and informatics. LumiCyte offers a range of protein mapping and validation services, together with information products designed to facilitate the early diagnosis of disease, monitoring of the stage and level of disease progression and monitor individual response to therapy.
About LumiCyte, Inc.
LumiCyte's (www.lumicyte.com) is a biotechnology company focused on the discovery and delivery of new medical knowledge. LumiCyte uses its proprietary protein BioChips and informatics technologies to generate and distribute new medical knowledge enabling the early detection of disease onset, classification of disease type and level of progression, and the monitoring of individual response to therapy. LumiCyte and its clients are focused on the discovery, validation and rapid development of new diagnostic and therapeutic opportunities. Established in 1999, LumiCyte's corporate offices and production facilities are located in Fremont, CA.
Contacts:
Chris Gardner / Mark Swallow,
HCC De Facto Group plc
Media Relations
+44 (0)20 7496 3300
c.gardner@hccdefacto.com
Louise Bono
LumiCyte, Inc.
Director, Marketing Communications
+1 (510) 226-3957
lbono@lumicyte.com